2014 Angiotensin Gordon Research Conference and Gordon Research Seminar

描述(申请人提供)：肾素-血管紧张素系统(RAS)在几乎所有心血管疾病中都起着至关重要的作用，而阻断该系统的药物目前被广泛使用。可以区分为三类(肾素抑制剂、血管紧张素转换酶抑制剂和血管紧张素Ⅱ1型(AT1)受体拮抗剂)，本质上都阻断了相同的肾素-血管紧张素-AT1受体途径。尽管多年来一直被认为“封锁越多越好”，但最近的试验(OnTarget，海拔)表明情况并非如此。事实上，在可能略有好处的同时，也有更多的副作用(低血压、高钾血症、肾功能障碍)。因此，显然，我们已经达到了阻断这条途径所能获得的最大好处，我们需要新的途径来干扰。事实上，在过去的几年里，出现了许多值得探索的新的RAS途径：(PRO)肾素受体、AT2受体(似乎受到血管紧张素II代谢物-(2-8)的刺激)和ACE2-血管紧张素-(1-7)-mas受体途径。此外，血管紧张素II刺激醛固酮的合成和释放(因此该系统也被称为肾素-血管紧张素-醛固酮系统，RAAS)。醛固酮受体拮抗剂现在是治疗难治性高血压的重要工具，同时出现了新的醛固酮受体(如GPR30)，醛固酮合成酶抑制剂正在作为潜在的治疗方式进行测试。第一批AT2受体(ANT)激动剂目前正在进行临床评估，这也是对各种干扰ACE2-血管紧张素-(1-7)-Mas受体途径的药物(例如，在急性呼吸应激综合征中)的评估。显然，目前，RA(A)的S领域正在迅速超越该系统的经典终末产物血管紧张素II，许多新药开始涌现，包括作用于血管紧张素II的一个特定信号通路的药物(偏向AT1受体激动剂)。血管紧张素GRC是唯一一次在一次会议上将这些议题聚集在一起的会议。它是RAS最新发现的讨论场所，有基础科学家和临床医生参与，结合GRS研讨会也吸引了许多来自学术界和工业界的年轻研究人员。允许他们的互动将有助于推动该领域的发展，从而使多种新药尽快提供给患者。

DESCRIPTION (provided by applicant): The renin-angiotensin system (RAS) plays a vital role in virtually every cardiovascular disease, and drugs blocking this system are currently widely used. Three classes can be distinguished (renin inhibitors, ACE inhibitors and angiotensin II type 1 (AT1) receptor antagonists), which in essence all block the same renin- angiotensin-AT1 receptor pathway. Although for many years it was argued 'the more blockade, the better', recent trials (ONTARGET, ALTITUDE) have shown that this is not the case. In fact, at perhaps slightly more benefit, there are also more side effects (hypotension, hyperkalemia, renal dysfunction). Clearly therefore, we have reached the maximum benefit that can be obtained from blocking this pathway, and we need new pathways to interfere with. Indeed, in the last few years multiple new RAS pathways have emerged that are worth exploring: the (pro) renin receptor, the AT2 receptor (which appears to be stimulated by an angiotensin II metabolite, angiotensin-(2-8)) and the ACE2-angiotensin-(1-7)-Mas receptor pathway. In addition, angiotensin II stimulates the synthesis and release of aldosterone (hence the system is also called the renin-angiotensin- aldosterone system, RAAS). Aldosterone receptor antagonists are now important tools in resistant hypertension, whereas simultaneously new aldosterone receptors emerge (e.g., GPR30), and aldosterone synthase inhibitors are being tested as potential treatment modalities. The first AT2 receptor (ant) agonists are currently being evaluated clinically, and this is also tre for various drugs interfering with the ACE2- angiotensin-(1-7)-Mas receptor pathway (e.g., in acute respiratory stress syndrome). Clearly, at present, the RA(A)S field is rapidly moving ''beyond'' angiotensin II, the classical end-product of this system, and many new drugs start to emerge, also including drugs that acts on one specific signaling pathway of angiotensin II (''biased AT1 receptor agonists''). The Angiotensin GRC is the only meeting where these topics come together in one meeting. It is THE discussion place for the latest discoveries in the RAS, involving basic scientists and clinicians, and combined with a GRS Seminar also attracts a lot of young investigators from academia and industry. Allowing their interaction will help to move the field forward, thus making multiple new drugs available to patients ASAP.